Pterygium. Excl.psudopterygium(H11.8)
Conditions
Interventions
Intervention 1: Group a: 1month preoperative subpterygeal injection of 0.1 cc mitomycin C. Intervention 2: Group b: ? month preoperative subpterygeal injection of 0.1 cc bevacizumab.
Treatment - Drugs
Group a: 1month preoperative subpterygeal injection of 0.1 cc mitomycin C
Group b: ? month preoperative subpterygeal injection of 0.1 cc bevacizumab
Sponsors
Voice Chancellor for Research - Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Primary pterygium Exclusion criteria;: Pregnancy ; history of pterygium surgery; glaucoma; trachoma ; autoimmune disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pterygium thickness. Timepoint: Preoperative subpterygeal njection and 1 month after injectin of mitomycin C and bevacizumab. Method of measurement: Anterior segment OCT.;Endothelial cell count. Timepoint: Preoperative subpterygeal injection and 1 ,3, 6 month after pterygium surgery. Method of measurement: Specular microscopy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate of pterygium. Timepoint: 6 months after pterygium surgery. Method of measurement: Eye examination with Slit-lamp biomicroscope. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid khakshoor
Mashhad University of Medical Sciences
Outcome results
None listed